Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Intel Corp (INTC) vs ResMed Inc. (RMD) Price & Performance

Intel CorpTrade
ResMed Inc.Trade

Price performance (Past 24H)

Key statistics

Intel Corp vs ResMed Inc. — how do they compare? Intel Corp trades at $99.92 (market cap $491.89B), while ResMed Inc. trades at $223.62 (market cap $31.92B). The key difference: Intel Corp is far larger — about 15.4× ResMed Inc.'s market cap, and Intel Corp pays the higher dividend (2.24%). Which is the better fit depends on your goals.

INTCRMD
Market Cap
$491.89B$31.92B
Volume
43,552,012
Sector
TechnologyHealth
52-Week High
$140.94$293.73
52-Week Low
$21.81$182.82
Enterprise Value
$512.70B$31.28B
Dividend Yield
2.24%1.2%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Intel Corp

No Aura AI signal available yet.

ResMed Inc.

ResMed (RMD) trades at $211.94, down 5.06% on the day, following a Q4 2026 earnings beat but weaker fiscal 2027 revenue guidance. The stock shows strong fundamentals with a 26.94% net income margin and consistent earnings beats, while technical indicators are neutral with support at $204 and resistance at $218. Recent news highlights growth in sleep device demand but concerns over sales forecasts.

Outlook remains mixed: robust profitability and a $235 consensus price target suggest upside, but near-term pressure from guidance and technical neutrality poses risks. Investors should weigh solid financial health against market sentiment shifts.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Intel Corp

Intel Corporation designs, manufactures, and sells computer components and related products. The Company major products include microprocessors, chipsets, embedded processors and microcontrollers, flash memory, graphic, network and communication, systems management software, conferencing, and digital imaging products.

Read more on INTC

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD